RxDoctor Payments Data
★ My doctorsLook up a doctor →

Ashley Owyang

Optometrist · Long Beach, CANPI 1245513571

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $31,950 of the $50,354 with a category attached, or 63.5%. Alcon accounts for 63.5% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $34,686 and has fallen 91.3% since, to $3,005 in 2025. Among optometrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$50,354in general payments, 2019–2025

Across 630 payments — averaging $79.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$32K
  • AbbVie$2K
  • Rxsight Inc$2K
  • Glaukos Corporation$2K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
  • Aerie Pharmaceuticals, Inc.$1K
  • plus $10K from 28 others
$66,368in research payments, 2019–2025

Across 40 payments — averaging $1659.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Glaukos Corporation$66K

What the payments were for

  • Consulting fees$31,95063%
  • Speaking & faculty fees$7992%
  • Food & beverage$16,93834%
  • Education$5461%
  • Gifts$1210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon74$31,993
AbbVie(2 entities)72$2,298
Rxsight Inc8$2,014
Glaukos Corporation32$1,636
Bausch & Lomb, A Division Of Bausch Health US, LLC83$1,322
Aerie Pharmaceuticals, Inc.59$1,202
Oyster Point Pharma, Inc.19$1,196
Bausch & Lomb Americas Inc.43$965
Sight Sciences, Inc.23$927
Sun Pharmaceutical Industries Inc.37$864
Mallinckrodt Hospital Products Inc.34$781
Biotissue Holdings Inc.27$639
Optovue, Inc.3$618
Dompe US, Inc.15$563
Tarsus Pharmaceuticals, Inc.14$533
Lensar, Inc.1$516
Kala Pharmaceuticals, Inc.16$304
Alcon Research LLC6$271
Amgen7$251
Shire North American Group Inc12$221
Novartis10$206
ANI Pharmaceuticals, Inc.8$161
Nova Eye, Inc.2$150
Eyevance Pharmaceuticals LLC7$138
Carl Zeiss Meditec USA, Inc.1$131
Carl Zeiss Meditec, Inc.2$116
Harrow Eye, LLC4$89
Thea Pharma Inc.3$66
Johnson & Johnson Surgical Vision, Inc.3$61
Ivantis, Inc1$48
NEW World Medical,inc.1$20
Ocular Therapeutix, Inc.1$20
Beaver-visitec International, Inc.1$18
Staar Surgical Company1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,354 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California →

Medicare billing

Part B allowed, 2024
$22,344
Medicare patients
110
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other optometrist in Long Beach

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →